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5-Aminoimidazole-4-carboxamide ribonucleoside-induced
autophagy ﬂux during differentiation of monocytic
leukemia cells
Vilma Dembitz, Hrvoje Lalic and Dora Visnjic
Pharmacological modulators of AMP-dependent kinase (AMPK) have been suggested in treatment of cancer. The biguanide
metformin and 5-aminoimidazole-4-carboxamide ribonucleoside (AICAR) have been reported to inhibit proliferation of solid tumors
and hematological malignancies, but their role in differentiation is less explored. Our previous study demonstrated that AICAR
alone induced AMPK-independent expression of differentiation markers in monocytic U937 leukemia cells, and no such effects
were observed in response to metformin. The aim of this study was to determine the mechanism of AICAR-mediated effects and to
test for the possible role of autophagy in differentiation of leukemia cells. The results showed that AICAR-mediated effects on the
expression of differentiation markers were not mimicked by A769662, a more speciﬁc direct AMPK activator. Long-term incubation
of U937 cells with AICAR and other differentiation agents, all-trans-retinoic acid (ATRA) and phorbol 12-myristate 13-acetate,
increased the expression of the autophagy marker LC3B-II, and these effects were not observed in response to metformin. Western
blot and immunoﬂuorescence analyses of U937 cells treated with baﬁlomycin A1 or transfected with mRFP-GFP-LC3 proved that
the increase in the expression of LC3B-II was due to an increase in autophagy ﬂux, and not to a decrease in lysosomal degradation.
3-Methyladenine inhibited the expression of differentiation markers in response to all inducers, but had stimulatory effects on
autophagy ﬂux at dose that effectively inhibited the production of phosphatidylinositol 3-phosphate. The small inhibitory RNA-
mediated down-modulation of Beclin 1 and hVPS34 had no effects on AICAR and ATRA-mediated increase in the expression of
differentiation markers. These results show that AICAR and other differentiation agents induce autophagy ﬂux in U937 cells and
that the effects of AICAR and ATRA on the expression of differentiation markers do not depend on the normal levels of key proteins
of the classical or canonical autophagy pathway.
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INTRODUCTION
Several studies have suggested that drugs that modulate activity
of AMP-activated kinase (AMPK) have potential for the treatment
and prevention of cancer. The biguanide metformin, a widely used
drug for the treatment of type 2 diabetes, and 5-aminoimidazole-
4-carboxamide ribonucleoside (AICAR, acadesine) have been
reported to exert antiproliferative effects in various solid tumors
and hematological malignancies, but their role in differentiation
has been less explored.1,2 Although both drugs activate AMPK, an
evolutionary conserved serine/threonine kinase that is activated
whenever the energy level in the cell is low and the ratio of AMP
to ATP increased, an increasing number of studies demonstrate
that majority of beneﬁcial effects of metformin and AICAR are
actually AMPK-independent.3,4 Our recent study demonstrated
that AICAR alone induced the expression of cell surface markers
associated with mature monocytes and macrophages in mono-
cytic U937 cells.5 However, no signiﬁcant increase in the
expression of differentiation markers was observed in U937 cells
treated with metformin alone, although the effects on prolifera-
tion and survival were similar to the ones observed in the
presence of AICAR.
It is still unknown which are the mechanisms responsible for
AICAR-mediated effects in acute myeloid leukemia (AML) cell lines.
Within the cell, AICA-ribonucleoside could be phosphorylated by
adenosine kinase into AICA-ribonucleotide or ZMP, which is an
analog of 5′-AMP; ZMP then binds to γ regulatory subunit and
activates AMPK in a similar manner to AMP.6 Although we
detected time- and dose-dependent increase in the level of Thr-
phosphorylated AMPK, a signiﬁcant decrease in AMPK expression
that was achieved by using commercially available siRNA
sequences in U937 cells had no signiﬁcant effects on the AICAR-
mediated effects on the number of viable cells or the expression of
differentiation markers.5 Therefore, present studies are aimed to
determine the mechanism responsible for beneﬁcial effects of AICAR
in AML cells and to further elucidate signaling mechanisms responsible
for differentiation of U937 cells in response to other inducers.
In chronic myelogenous leukemia (CML) cell lines, AMPK-
independent cell death induced by AICAR involved autophagy,
the major intracellular pathway for the selective degradation of
cytoplasmic organelles and long-lived proteins.7 Although initially
described as a protective mechanism that allowed cells to survive
in the absence of nutrients, the autophagy has been recently
implicated in several other conditions, including cell death,
neurodegeneration, immunity, cancer and differentiation.8,9
Autophagy is mediated by autophagy-related (ATG) genes that
are evolutionary conserved from yeasts to mammals; a key
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initiation signal is provided by a complex consisting of Beclin 1 (or
Atg6), class III phosphatidylinositol 3-kinase (PI3KC3 or Vps34),
Vps15 and Atg14. In unstressed cells, autophagy is inhibited by
mammalian target of rapamycin complex 1 (mTORC1). Therefore,
inhibition of mTOR by either rapamycin or AMPK activation
promotes autophagy.8 Recent studies pointed to the role of
autophagy in differentiation of some leukemia cell lines, including
all-trans-retinoic acid (ATRA)-induced differentiation of acute
promyelocytic leukemia NB4 cells,10–12 vitamin D3-mediated
differentiation of myeloblastic HL-60 cells13 and megakaryocytic
differentiation of CML K562 cells in response to phorbol 12-
myristate 13-acetate (PMA) or lapatinib.14,15
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In the present study, we tested for the possible role of
autophagy in AICAR-mediated differentiation of monocytic U937
leukemia cells. The results of the study showed that long-term
incubation of U937 with AICAR and other inducers of differentia-
tion induced autophagy ﬂux that was not observed in cells treated
with metformin. However, AICAR-mediated increase in the
expression of differentiation markers did not depend on the
presence of key proteins of canonical autophagy pathway.
RESULTS
To corroborate the ﬁnding that AICAR-mediated effects are AMPK-
independent, we ﬁrst tested the effects of A769662, a more
speciﬁc direct AMPK activator, on the proliferation and differentia-
tion of monocytic U937 cells. Although the incubation with
A769662 for 96 h reduced the number of viable U937 cells
comparable to the effect of AICAR (data not shown), there were no
effects on the level of either CD64 or CD11b (Figure 1a). Therefore,
we concluded that AICAR-mediated effects in leukemia cell lines
cannot be mimicked by a more speciﬁc AMPK activator.
To test for the possible role of AICAR as an autophagy inducer,
we measured the level of LC3B, which is widely used as a reporter
of autophagosome formation.16 During autophagy, LC3B is
speciﬁcally cleaved to form LC3-I, and cytosolic LC3-I is lipidated
to the autophagosome membrane-bound LC3-II form that
migrates faster in SDS-PAGE. For western blot analyses, U937
cells were ﬁrst incubated in the presence of AICAR, other
differentiation inducers (ATRA, PMA) and metformin. Total cell
lysates were isolated 3 and 48 h after the addition of agents and
analyzed for the expression of LC3B. As shown in Figure 1b, all
agents slightly increased the level of LC3B-II after 3 h. However,
after 48 h, the ratio of LC3B-II to actin was signiﬁcantly increased
in cells treated with AICAR and other differentiation agents, while
there was no increase in cells treated with metformin.
The increase in LC3B-II levels could be related to either
enhanced formation of LC3B-II, due to an increase in autophagic
activity, or reduced turnover, due to an impairment of the
degradation. To distinguish between the two, the cells can be
treated by baﬁlomycin A1 that inhibits H+-ATPase and blocks
lysosomal degradation so that any further accumulation of LC3B-
II-positive autophagosomes would be the evidence of autophagic
ﬂux.16 As shown in Figure 1c, baﬁlomycin A1 alone increased the
level of LC3B-II and had additive effects on the levels of LC3B-II in
cells treated with AICAR and other differentiative agents, which
indicated an increase in autophagic ﬂux. Again, metformin had no
such effects; the LC3B-II/actin ratio in cells treated with combina-
tion of baﬁlomycin A1 and metformin was higher than the ratio in
cells treated with metformin, but lower than the ratio in cells
treated with baﬁlomycin A1 alone. As shown in Figure 1c, the level
of p62/SQSTM1, an LC3-interacting protein degraded in the
autolysosomes, was increased in response to AICAR in accordance
with previously published results that demonstrated p62/SQSTM1
upregulation during differentiation of AML cells.17 In addition, to
check for targets downstream of AMPK, phosphorylation of Ulk1
on Ser555 as a trigger for mTOR-independent autophagy was
examined in cells treated with differentiation agents. As shown in
Figure 1d, in cells treated with AICAR for 48 h the level of Ulk1
phosphorylated on Ser555 was decreased, further suggesting that
AICAR-mediated effects on U937 cells are AMPK-independent.
Additionally, the endogenous LC3B protein was detected by
immunoﬂuorescence using the same anti-LC3B antibody
(Figure 1e). The analysis by confocal microscopy revealed that
immunoﬂuorescent staining changed from diffuse to more
punctate in cells treated with AICAR for 48 h, and these changes
were more pronounced in cells that were treated in the presence
of baﬁlomycin A1 for last 3 h. Again, no similar effects were
observed in cells treated with metformin.
To further verify the increase in autophagic ﬂux, U937 cells were
transfected with plasmid containing LC3B gene fused with genes
encoding mRFP and GFP.18 The principle of the method is based
on different sensitivities of GFP and mRFP proteins to changes in
pH; in acidic environment, green ﬂuorescence of GFP is quenched,
while the red ﬂuorescence of mRFP is maintained. As shown in
Figure 1f, control U937 cells transfected with mRFP-GFP-LC3B
showed some basal level of autophagy. The addition of AICAR
increased the number of red dots and these effects were lacking
in cells treated with metformin. As expected, baﬁlomycin A1
increased the level of both green and red ﬂuorescence.
To further test for the role of autophagic ﬂux in differentiative
effects of agents, the effects of pharmacological modulators of
autophagy were tested in U937 cells. Chloroquine, an inhibitor of
lysosomal degradation, has been previously used in concentration
ranging from 2.5 to 50 μM to block late autophagy pathway in
K562, NB4, primary AML cells and monocytes.19–22 In this study,
chloroquine was used in concentration of 25 μM in which it
exerted only mild cytotoxic effects and no stimulatory effects on
the expression of differentiation markers. As shown in Figure 2a,
chloroquine inhibited an increase in the expression of CD11b and
CD64 in response to AICAR, but had no effects on ATRA-stimulated
increase in the expression of CD11b and further increased the
expression of CD64.
Although pharmacological inhibition of mTORC1 by rapamycin
promoted autophagy in the model of yeasts grown in the
presence of nutrients as well as in various tumor cell lines,23
different effects of mTOR inhibitors on the expression of
differentiation markers have been reported in leukemia cell
lines.24–27 As shown in Figure 2a, the presence of 20 nM
rapamycin prevented an increase in the expression of CD64 and
Figure 1. AICAR and other differentiative agents induce autophagy in U937 cells. (a) U937 cells were treated with AICAR (0.5 mM) and direct
AMPK agonist A769662 (100 or 200 nM) for 96 h and the expression of differentiation markers was analyzed by ﬂow cytometry. Results are
mean± S.E.M. of three independent experiments. *Po0.05. (b) AICAR and other differentiation inducers increase the expression of LC3B-II, an
autophagy marker. Total cell lysates were isolated 3 or 48 h after addition of AICAR (0.5 mM), ATRA (1 μM), metformin (15 mM) or PMA (50 nM)
and analyzed by western blot. Representative immunoblot from three independent experiments is shown. Blots were scored by densitometry
and graphs represent mean± S.E.M. of LC3B-II/actin ratios from three independent experiments. (c) Cells were treated for 48 h as indicated
above and baﬁlomycin (50 nM) was added during the last 3 h of incubation for the assessment of autophagic ﬂux. Representative immunoblot
from three independent experiments is shown. Graph represents mean± S.E.M. of LC3B-II/actin ratios from three independent experiments.
(d) AICAR does not increase phosphorylation of Ulk1 on Ser555. Cells were treated as indicated above and representative immunoblot from
three independent experiments is shown. (e) Immunolabeling of U937 cells treated with AICAR (0.5 mM) and metformin (15 mM)
demonstrates that AICAR induces formation of LC3B puncta. Baﬁlomycin (50 nM) was added as described above and used for the assessment
of autophagic ﬂux. Representative images of confocal microscropy from three independent experiments are shown. Images are × 63 with × 2
times digital zoom, scale bar= 10 μm. (f) Analysis of autophagic ﬂux in AICAR-treated U937 cells stably transfected with mRFP-GFP-LC3B. Cells
were incubated for 48 h with AICAR (0.5 mM) or metformin (15 mM). Baﬁlomycin (50 nM) was added during the last 3 h of incubation.
Representative images of confocal microscopy from two independent experiments performed in duplicates are shown. Images are × 63 with
× 4 times digital zoom, scale bar= 10 μm.
Autophagy during differentiation of U937 cells
V Dembitz et al
3
Ofﬁcial journal of the Cell Death Differentiation Association Cell Death Discovery (2017) 17066
CD11b induced by AICAR. However, rapamycin decreased the
level of CD64 but had no signiﬁcant effects on the level of CD11b
in ATRA-treated cells, as previously described.27
3-Methyladenine (3-MA) is the most commonly used inhibitor of
autophagy, which acts in order to inhibit the early stage of the
pathway by blocking hVPS34. Previous studies performed on
ATRA-differentiated leukemia cells10,20 or GM-CSF-differentiated
monocytes22 used 3-MA in the concentrations of 5 and 10 mM. As
shown in Figure 2b, the same concentrations of 3-MA decreased
the number of viable cells and abolished differentiative effects of
AICAR, ATRA and PMA.
Although used as an inhibitor of autophagy, 3-MA is not highly
speciﬁc for hVPS34 as it inhibits both PI3K class III (hVPS34) and
PI3K class I (PI3KC1). Two classes of PI3K enzymes have opposite
effects on autophagy; the activation of hVPS34 induces, and the
activation of PI3KC1 inhibits autophagy. Recent study reported
stimulatory effects of 3-MA on autophagy in cells that were
incubated in medium containing all nutrients, and these effects
were explained by differential temporal effects of 3-MA on hVPS34
and PI3KC1.28 To check whether the presence of 3-MA for 48 h
efﬁciently decreased the activity of hVPS34 in our model, the level
of PtdIns(3)P was measured by commercial Mass ELISA Assay. As
shown in Figure 3a, the presence of 5 mM 3-MA signiﬁcantly
decreased the level of PtdIns(3)P in control cells and cells treated
with AICAR for 48 h.
Once we proved that the activity of hVPS34 was signiﬁcantly
inhibited after 48 h of treatment with 3-MA, the effect of the
inhibitor on autophagy was determined by measuring the level of
LC3B-II. As shown in Figure 3b, 48 h incubation of U937 cells with
3-MA increased the accumulation of LC3B and the levels were
further increased in cells treated with combination of agents and
3-MA. Finally, additional experiments were performed on U937
cells stably transfected with plasmid containing mRFP-GFP-LC3B.
As shown in Figure 3c, the punctate pattern of 3-MA-treated cells
was different than the pattern observed in baﬁlomycin-treated
cells, suggesting that an increase in the level of LC3B in 3-MA-
treated cells is due to an increase in autophagy ﬂux. Therefore, we
concluded that the inhibitory effects of 3-MA on the expression of
differentiation markers in our model were not due to an inhibition
of autophagy.
Although our ﬁndings ruled out the possible role of 3-MA as a
speciﬁc inhibitor of autophagy, the correlation between low level
of PtdIns(3)P and the inhibitory effect on the expression of
differentiation markers prompted us to further elucidate the
possible role of hVPS34 by siRNA-mediated downregulation.
Figure 4a shows the results of three independent experiments
in which the exponentially growing cells were transfected by
siRNA and plated 24 h after transfection in the presence of agents.
The efﬁciency of downregulation was tested 3 and 48 h after
addition of agents by western blot, and the expression of CD64
and CD11b 48–72 h after addition of agents. As shown in Figure 4a,
a decrease in the level of hVPS34 had no effects on AICAR- and
ATRA-mediated increase in the expression of markers. In some
experiments, cells transfected with siRNA targeting hVPS34 had
lower expression of CD11b upon stimulation with PMA.
It is difﬁcult to estimate the effects of hVPS34 downregulation
on autophagy, since different effects of the lack of the hVPS34
have been reported on the expression of LC3B as an autophagy
marker,29 including even an increase in LC3-II due to decreased
autophagic degradation.30 When we tested the effects of hVPS34
down-modulation in U937 cells, no change in the expression of
LC3B was detected in cells after transfection (Figure 4b).
Canonical or classical autophagy pathway that is activated
during starvation includes the formation of complex of hVPS34
with protein Beclin 1.8 We next tested for the level of Beclin 1 in
cells transfected with hVPS34 siRNA. As shown in Figure 4c, a
decrease in the level of Beclin 1 was associated with a decrease in
the level of hVPS34. Although the level of LC3B-II was slightly
decreased in AICAR-treated cells (Figure 4d), a decrease in the
level of hVPS34/Beclin 1 proteins had no effects on the increase in
the expression of CD11b and CD64 induced by AICAR and ATRA
(data not shown).
In accordance with the current guidelines,16 it is necessary to
verify the autophagy dependence of a phenotype by knocking
down several different ATG genes. In other Beclin 1-independent
models, the level of LC3B was shown to depend on the expression
of ATG7.31 Therefore, U937 cells were next transfected with 28 nM
siRNA containing one sequence speciﬁc for ATG7. As shown in
Figure 5a, a signiﬁcant decrease in the level of ATG7 protein was
paralleled with a decrease in the expression of differentiation
markers in cells treated with AICAR and ATRA.
Once we observed a correlation between low level of ATG7
protein and inhibition of AICAR and ATRA-mediated increase in
the expression of CD64 and CD11b, we tried to conﬁrm that a
phenotype results from speciﬁc siRNA-induced silencing of ATG7
gene and not from potential off-target effects of individual siRNA.
Pooling of multiple siRNAs to the same target have been
suggested to reduce off-target silencing.32 Therefore, we tried to
reproduce a phenotype using four different autophagy-inhibiting
siRNAs to the same ATG7 gene. As shown in Figure 5b, although
transfection with pool of four siRNAs signiﬁcantly decreased the
level of ATG7 in two independent experiments, no effects of ATG7
down-modulation on the expression of CD64 and CD11b were
observed in cells differentiated in the presence of agents.
Finally, U937 cells were simultaneously transfected with siRNA
targeting hVPS34 and ATG7 and agents were added again 24 h
after transfection. As shown in Figure 6, although the levels of
ATG7 and hVPS34 were decreased in lysates 48 h after addition of
agents, no differences in the expression of markers were observed
in cells treated with differentiation agents.
DISCUSSION
Our previous study showed that AICAR-mediated effects on the
cell viability and the expression of differentiation markers
occurred independently of the level of siRNA-downregulated
AMPK. Both AICAR and metformin were shown to increase the
phosphorylation of AMPK on Thr172, which was used as a marker
of AMPK activation, and decreased the phosphorylation of p70
S6K, a marker of mTOR inhibition, but metformin had no effects on
the expression of differentiation markers.5 Results of our present
study show that AICAR-mediated effects cannot be mimicked by
speciﬁc AMPK-activator A769662, which further corroborates the
hypothesis that AICAR-mediated effects are AMPK-independent.
These results are in agreement with increasing number of studies
showing that the majority of agents that are commonly used as
AMPK agonists, including metformin and AICAR, display AMPK-
independent effects on cell proliferation, metabolism and
differentiation.3,4,7,33
Results of the present study demonstrate that AICAR and other
differentiation agents increase autophagy as measured by an
increase in the level of LC3B-II. Furthermore, all data obtained with
baﬁlomycin A1 or mRFP-GFP-LC3 proved that the increase in the
expression of LC3B-II was due to an increase in the autophagy ﬂux,
and not to a decrease in lysosomal degradation. Again, different
effects of AICAR and metformin on autophagy ﬂux further suggest
that their effects are AMPK-independent. Although the activation
of AMPK and inhibition of mTOR are well known inducers of
autophagy through activation of ULK1 and hVPS34,8 several
studies demonstrated that autophagy can occur in the absence of
AMPK in response to pharmacological AMPK modulators.7,34,35 The
effects of AICAR on the increase of LC3B-II in U937 cells correlates
well with the effects of other differentiative agents in U937 cells,
and the effects of both ATRA and PMA on the level of LC3B-II are
similar to the ones previously described in NB4(refs 10,11,12) or
K562(ref. 14) cell lines. In NB4 cells, the role of autophagy in
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differentiative effects of ATRA was proposed based on the
inhibitory effects of 3-MA on the expression of CD11b.10 Although
both chloroquine and 3-methyladenine prevented AICAR-
mediated increase in the expression of CD11b and CD64 in our
model, we cannot conclude that autophagy is necessary for
differentiative effects. Our additional studies showed that 3-MA
actually increased the level of LC3B-II, even when applied at
concentration and time interval that efﬁciently inhibited the
activity of hVPS34. Therefore, the present study further corrobo-
rate the hypothesis that 3-MA cannot be used as a speciﬁc
pharmacological inhibitor of autophagy, at least not under
nutrient-rich conditions.28
In the classical autophagy pathway, the key initiation signal is
provided by hVPS34/Beclin 1 complex, and the elongation of
autophagosome is dependent on ATG7.8 The literature search
reveals many studies in which the selection of various autophagy
knockdown targets in leukemia cell lines has different effects on
differentiation, and the simplest explanation for these ﬁndings
could be that the role of autophagy in leukemia cell line may be
cell type and/or agonist dependent. In K562 cells, shRNA-
mediated knockdown of ATG7 increased CD71 and glycophorin
as markers of erythroid differentiation,19 but in NB4 cells the lack
of ATG7 protein inhibited ATRA-mediated increase in CD11b.20
The downregulation of Beclin 1 by siRNA moderately, but
signiﬁcantly, inhibited vitamin D3-mediated increase in CD14 in
HL-60 cells.13 In NB4 cells, shRNA-mediated downregulation of
hVPS34 inhibited the expression of CD11b,12 but downregulation
of Beclin 1 had no effects on ATRA-mediated increase in CD11b12
or CD11c.11 The effects of the downregulation of the same protein
correlate better with the marker tested than with the mode of
downregulation (shRNA versus siRNA) since downregulation of
p62/SQSTM1 by shRNA36,37 inhibited ATRA-mediated increase in
CD11b, but had no effects on ATRA-mediated increase in CD11c.17
There are no reports regarding the role of autophagy in
differentiation of U937 cells, but the role of autophagy was
investigated in differentiation of primary monocytes into macro-
phages. In CSF-1-stimulated monocytes, siRNA for Beclin 1, ATG7
and ATG5 decreased both the level of LC3B and CSF-1-mediated
increase in CD71 and CD163.38 However, in contrast to AICAR-
mediated effects in U937 cells, CSF-1-mediated effects on
differentiation and autophagy were AMPK-dependent.39 Current
guidelines in autophagy research suggest focusing on in vivo
models instead of cell lines.40 The analyses of Atg7f/f;Vav-Cre mice
lacking Atg7 in hemopoietic system revealed severe anemia and
lymphopenia and self-renewal defects in hemopoietic stem cells
(HSC), but the number of CD11b-positive cells was actually
increased resembling myelodysplastic syndrome.41,42 An extensive
analysis of macrophages of Atg7f/f;Vav-Cre mice revealed a
modiﬁed response to LPS and IFN-γ-stimulation, but no differ-
ences in the expression of CD11b were detected, and the level of
CD64 was not investigated.43 The analysis of Atg7f/f;Lyz-Cre mice
in which the Atg7 deletion was limited to myeloid cell lineage
revealed normal number of myeloid cells and normal physiologic
induction of monocyte to macrophage differentiation. However, in
contrast to HSC from Atg7f/f;Vav-Cre mice in which Atg7 deletion
impairs autophagy, Atg7-deﬁcient cells of Atg7f/f;Lyz-Cre mice
maintain an active Atg7-independent alternative autophagy that
depended on Rab9.44
Although results of our study suggest that canonical autophagy
is not necessary for differentiation induced by AICAR and ATRA in
U937 cells, we cannot completely rule out the possibility that
minimal levels of Atg7, Vps34 or Beclin 1 in siRNA-treated cells are
sufﬁcient to allow differentiation to proceed. In comparison to
other AML cell lines, U937 cells have higher activity of Akt and
mTOR, probably due to heterozygous deletion of phosphatase
and tensin homolog (PTEN),45,46 and loss of PTEN has been
reported to inhibit autophagy without affecting LC3 lipidation,47
which raises a possibility that even low level of autophagy in U937
Figure 2. The effect of pharmacological modulators of autophagy
on the expression of differentiation markers. (a) U937 cells were
incubated with AICAR (0.5 mM) and ATRA (1 μM) for 96 h.
Chloroquine (25 μM) and rapamycin (20 nM) were added 15 min
before addition of differentiation agents. (b) U937 cells were
incubated with AICAR (0.5 mM), ATRA (1 μM), metformin (15 mM)
and PMA (50 nM) for 48 h. 3-MA (5 or 10 mM) was added 15 min
before addition of agents tested. The number of viable cells was
determined by trypan blue exclusion and the expression of
differentiation markers was analyzed by ﬂow cytometry. Results
are mean± S.E.M. of at least three independent experiments.
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cells may be sufﬁcient for differentiation to occur. Another
possibility is that an increase in lipidated LC3B is not necessary
for the expression of surface markers, but occurs simultaneously
during differentiation since LC3B has been reported in both LC3B-
associated phagocytosis and antigen presentation.48 Models of
oncogene-transformed cell lines grown under nutrient-rich con-
ditions and exposed to different agents are obviously different
from a simple model of starving yeast cells in which principal
members of canonical autophagy pathway, were initially
described. In last years, several studies have reported that many
inducers of autophagy ﬂux act independently from Beclin 1/Vps34
complex, especially inducers of either differentiation or
apoptosis.11,12,31,49
In conclusion, results of our study show that AMPK-independent
effects of AICAR-mediated differentiation include induction of
autophagy ﬂux that is common to other inducers of
Figure 3. PI3K class III (hVPS34) inhibitor 3-MA reduces PtdIns(3)P but increases the levels of LC3B-II and autophagic ﬂux. (a) U937 cells were
treated with AICAR (0.5 mM) or metformin (15 mM) for 48 h and lipids were extracted by chloroform–methanol procedure. The levels of PtdIns
(3)P were determined using Mass ELISA assay. Results are mean± S.E.M. of three independent experiments performed. (b) U937 cells were
incubated with AICAR (0.5 mM), ATRA (1 μM), metformin (15 mM) and PMA (50 nM). 3-MA (5 or 10 mM) was added 15 min before addition of
agents tested. Total cell lysates were isolated 48 h after addition of agents and analyzed by western blot. Representative immunoblot from
three independent experiments is shown. Blots were scored by densitometry and graph represents mean± S.E.M. of LC3B-II/actin ratios from
three independent experiments. (c) U937 cells stably transfected with mRFP-GFP-LC3B were incubated with 3-MA (5mM) for 48 h or
baﬁlomycin (50 nM) for 3 h. Representative images of confocal microscropy from two independent experiments performed in duplicates are
shown. Images are × 63 with × 4 times digital zoom, scale bar= 10 μm.
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Figure 4. Normal levels of hVPS34 are not required for AICAR-mediated differentiation of U937 cells. (a) Cells were transfected with siRNA
against hVPS34 and respective non-targeting siRNA was used as a negative control. AICAR (0.5 mM), ATRA (1 μM), metformin (15 mM) or PMA
(50 nM) were added 24 h after transfection. Total cell lysates were isolated 3 or 48 h after addition of agents and analyzed by western blot. The
expression of differentiation markers was analyzed by ﬂow cytometry 48 or 72 h after addition of agents. Western blot analyses and data
obtained by ﬂow cytometry are shown for each of the three independent experiments (Exp 1–3). (b, c) Cells were transfected with siRNA
against hVPS34 or respective non-targeting siRNA. AICAR (0.5 mM) or metformin (15 mM) were added 48 h after transfection. Total cell lysates
were isolated 3 or 48 h after addition of agents and analyzed by western blot for the expression of LC3B-II (b) or Beclin 1 (c). Representative
images of at least three independent experiments are shown. (d) Cells were transfected with siRNA against Beclin 1 or respective non-
targeting siRNA. AICAR (0.5 mM) was added 48 h after transfection. Total cell lysates were isolated 48 h after addition of AICAR and analyzed
by western blot. Representative images of at least three independent experiments are shown.
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Figure 5. The effect of decrease in Atg7 protein levels on the expression of differentiation markers. (a) Cells were transfected with siRNA
against Atg7 (one sequence) and respective non-targeting siRNA. AICAR (0.5 mM), ATRA (1 μM), metformin (15 mM) or PMA (50 nM) were
added 24 h after transfection. Total cell lysates were isolated 48 h after addition of agents and analyzed by western blot. The expression of
differentiation markers was analyzed by ﬂow cytometry 48 or 72 h after addition of agents. Western blot analyses and data obtained by ﬂow
cytometry are shown for each of the two independent experiments (Exp 1–2). (b) Cells were transfected with siRNA against Atg7 (four
sequences) and respective non-targeting siRNA. AICAR (0.5 mM), ATRA (1 μM), metformin (15 mM) or PMA (50 nM) were added 24 h after
transfection. Total cell lysates were isolated 3 or 48 h after addition of agents and analyzed by western blot. The expression of differentiation
markers was analyzed by ﬂow cytometry 48 or 72 h after addition of agents. Western blot analyses and data obtained by ﬂow cytometry are
shown for each of the two independent experiments (Exp 1–2).
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differentiation, including ATRA and PMA. However, the normal
levels of key proteins of canonical autophagy pathway, including
Beclin 1, hVPS34 and Atg7, are not necessary for differentiation of
U937 cells in response to AICAR.
MATERIALS AND METHODS
Chemicals
AICAR (A9978), 3-methyladenine (M9281) and chloroquine (C6628) were
purchased from Sigma (St Louis, MO, USA) and dissolved in sterile water to
stock concentrations of 100, 200 and 50 mM, respectively. 1,1-
Dimethylbiguanide hydrochloride (metformin, D150959), PMA (P8139)
and baﬁlomycin A1 (B1793) were obtained from Sigma and dissolved in
RPMI-1640 medium, 100% dimethylsulfoxide (DMSO) and ethanol to stock
concentrations of 1 M, 50 μM and 100 μM, respectively. ATRA (#554720)
and rapamycin (#553210) were purchased from Calbiochem (San Diego,
CA, USA) and dissolved in DMSO to stock concentrations of 1 mM and
20 μM, respectively. Anti-CD11b-FITC (IM0530) and anti-CD64-FITC
(IM1604), FITC-conjugated mouse immunoglobulin 1 (IgG1) (IM0639) were
purchased from Immunotech Beckman Coulter (Marseille, France). Cell lysis
buffer (#9803), antibodies against LC3B (#3868), p62/SQSTM1 (#5114),
Ser555 p-Ulk1 (#5869), Beclin 1 (#3495), PI3 Kinase Class III (#4263), Atg7
(#8558) anti-rabbit IgG (#7074) and anti-mouse IgG (#7076) conjugated to
Figure 6. The effect of simultaneous decrease in hVPS34 and Atg7 protein levels on the expression of differentiation markers. Cells were
transfected with siRNA against hVPS34 and Atg7 (four sequences) and respective non-targeting siRNA was used as a negative control. AICAR
(0.5 mM), ATRA (1 μM), metformin (15 mM) or PMA (50 nM) were added 24 h after transfection. Total cell lysates were isolated 48 h after
addition of agents and analyzed by western blot. The expression of differentiation markers was analyzed by ﬂow cytometry 48 h after addition
of agents. Western blot analyses and data obtained by ﬂow cytometry are shown for each of the three independent experiments (Exp 1–3).
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horseradish peroxidase were purchased from Cell Signaling Technology
(Beverly, MA, USA). Enhanced chemiluminescence (ECL) substrate was
obtained from Thermo Fisher Scientiﬁc (Waltham, MA, USA), and protein
assay from Bio-Rad Laboratories (Hercules, CA, USA; #500-0006) or Sigma
(B6916). A Neon Transfection System 100 μl Kit (#MPK10096) and anti-
rabbit IgG secondary antibody conjugated to Alexa Fluor 488 (A11034)
were purchased from Invitrogen (Carlsbad, CA, USA). Small interfering RNA
(siRNA) SignalSilence Unconjugated Control (#6568), SignalSilence Beclin 1
siRNA I (#6222) and II (#6246), SignalSilence Atg7 siRNA I (#6604) were
purchased from Cell Signaling Technology. ON-TARGETplus SMARTpool
Human ATG7 (L-020112-00), PIK3C3 (L-005250-00) and negative control
(D-001810-10) siRNA were obtained from Dharmacon (Lafayette, CO, USA).
Monoclonal anti-β-actin antibody (#A5441), propidium iodide (PI), RNaseA,
Igepal, color markers, bovine serum albumin, Triton X-100, sodium dodecyl
sulfate (SDS), leupeptin and phenylmethylsulfonyl ﬂuoride (PMSF) were
from Sigma, RPMI-1640, fetal bovine serum (FBS), penicillin/streptomycin
were from Gibco/Invitrogen (Grand Island, NY, USA) and G418 was from
Roche (Basel, Switzerland). Vectastain normal goat serum (FI-1200) and
Vectashield mounting medium (H-1000) were from Vector Laboratories Inc.
(Burlingame, CA, USA). Deoxyribonuclease I (D5025) was from Sigma.
PtdIns(3)P Mass ELISA Kit (K-3300) was from Echelon Biosciences Inc. (Salt
Lake City, UT, USA).
Cell culture
U937 cells were obtained from two sources: one was a kind gift from Dr.
Mirna Golemovic (Clinical Hospital Centre, Croatia) and another was
bought from European Collection of Animal Cell Cultures (ECACC no.
88112501; Porton, Salisbury, UK). The cells were maintained in RPMI-1640
supplemented with 10% heat-inactivated FBS, 2 mM L-glutamine, 50 U/ml
penicillin and 50 μg/ml streptomycin at 37 °C in a humidiﬁed atmosphere
containing 5% CO2.
For the experiments, cells were harvested, resuspended in fresh medium
containing FBS, L-glutamine and penicillin/streptomycin and seeded at a
concentration of 0.2 × 106/ml in six-well plates. The cells were incubated
for various time intervals in the presence of 0.5 mM AICAR, 1 μM ATRA,
15 mM metformin and 50 nM PMA. Autophagy modulators, chloroquine
(25 μM), 3-MA (5 or 10 mM) and rapamycin (20 nM), were added 15 min
prior to other agents. Baﬁlomycin was added for the last 3 h of incubation
at a ﬁnal concentration of 50 nM. At the end of incubation, the number of
viable cells was determined by trypan blue staining and hemocytometry.
Expression of surface markers
The expression of surface markers was determined by ﬂow cytometric
analysis, as previously described.50 Brieﬂy, cells were collected, washed and
incubated with FITC-conjugated monoclonal antibodies against CD11b
and CD64, or with their isotypic control for 20 min, washed and analyzed
using the FACSCalibur system and Cell Quest software (Becton Dickinson
Immunocytometry Systems, San Jose, CA, USA). Live cells were gated
based upon forward and side scatter patterns. A total of 15 000 events
were collected for each marker from the gated area detecting viable cells.
On a single ﬂuorescence histogram of the sample stained with isotypic
control, a cursor was set to include up to 1.0% of events as positive. To
determine the mean ﬂuorescence intensity (MFI) of the sample, MFI levels
of isotypic controls were deducted from MFI levels of the cells stained with
CD-speciﬁc antibodies.
Isolation of total cell lysates and western blot analysis
At the end of incubation, cells were collected by centrifugation, washed in
ice-cold PBS and incubated in 1 × cell lysis buffer containing freshly added
1 μM microcystin and 1 mM PMSF on ice. After 10 min, cells were further
disrupted by seven passages through a 23-gauge needle, incubated on ice
for 10 min and centrifugated at 14 000× g for 10 min. The supernatants
were collected and stored at − 80 °C. The protein concentration of each
sample was determined using Bradford protein assay (Bio-Rad or Sigma).
Western blot analysis was performed as previously described.46 Brieﬂy,
equal amounts of proteins (35–50 μg) in each sample were loaded onto
two parallel 8 or 12% SDS-polyacrilamide gels. Electrophoresis was carried
out using the Bio-Rad mini-Protean apparatus, and proteins were
transferred to nitrocellulose membranes (Whatman, Dassel, Germany)
using the Bio-Rad mini Trans-Blot system. After blocking for 30 min in TBS-
Tween buffer containing 5% (w/v) non-fat dried milk, membranes were
incubated with primary antibodies (1:20 000 for actin; 1:1000 for other
antibodies) overnight at 4 °C, and then with secondary antibodies (1:2000)
for 120 min at room temperature. Bands were visualized using the ECL kit.
Relative densitometric values for autoradiography signals were analyzed
with Adobe Photoshop CS version 8.0 software (San Jose, CA, USA).
Isolation of acidic lipids and competitive PtdIns(3)P Mass ELISA
Measurement of total cellular PtdIns(3)P levels was carried out using PtdIns
(3)P Mass ELISA Kit (Echelon) following the manufacturer’s instructions.
Brieﬂy, after 48 h incubation with AICAR (0.5 mM) and metformin (15 mM),
viable cells were counted and the volume adjusted so that each sample
contains the same number of cells (13–15 × 106). Neutral lipids were
isolated with methanol:chloroform (2:1) extraction and acidic lipids were
subsequentially isolated using methanol:chloroform: 12 N HCl (80:40:1).
Dried acidic lipids were stored at − 20 °C. For PtdIns(3)P measurement with
Mass ELISA assay, dried lipids were reconstituted in PBS with 0.05% Tween-
20 and 3% Protein Stabilizer and incubated for 30 min in a water bath
sonicator at room temperature. The quantities of PtdIns(3)P in each sample
were calculated by comparison with a standard curve derived from
measurements of PtdIns(3)P standards supplied by the manufacturer using
nonlinear regression analysis (GraphPad Prism Software, La Jolla, CA, USA).
siRNA transfection
Transfection with controls and indicated siRNAs targeting proteins of
interest was performed using the Neon transfection system (Invitrogen) as
previously described.5 Brieﬂy, the cells were collected in their exponential
growth, resuspended in transfection buffer at a concentration of 22 × 106
cells/ml and siRNAs were added at recommended concentrations. The
electroporation was carried out in a 100 μl tip, with single pulse, at a
voltage of 1050 V and pulse width of 50 ms. Following the electroporation,
100 μl of cell suspension was resuspended in 200 μl of RPMI-1640 with
10% FBS and 2 mM L-glutamine without penicillin/streptomycin, incubated
for 15 min at 37 °C and resuspended in the total volume of 5 ml RPMI
without antibiotics. Final concentrations of 28 nM siRNA against Beclin 1
and ATG7 (Cell Signaling Technologies) or 45–140 nM siRNA against
hVPS34 and ATG7 (Dharmacon) were used. Transfected cells were
incubated for 24 or 48 h, collected, resuspended in fresh medium and
plated in six-well plates for the differentiation experiments. An aliquot of
cells was used for the preparation of total cell lysates and the level of
downmodulated proteins was determined by western blot analysis.
Immunostaining for confocal microscopy
U937 cells were stained for LC3B in round bottom 5 ml tubes according to
the manufacturer’s instructions. Brieﬂy, cells were ﬁxed with ice-cold 100%
methanol at − 20 °C, blocked in 5% normal goat serum with 0.3% Triton
X-100, washed in PBS with addition of 0.1 mg/ml DNAse to prevent
clumping, stained with primary antibody at +4 °C overnight (1 : 200) and
with secondary antibody (1:600) at room temperature for 120 min. The
pellet of immunostained cells was resuspended in 20 μl Vectashield
mounting medium and mounted on slides. Images were taken using a
Zeiss LSM 510 Meta confocal microscope with a plan-apochromat × 63 1.4
NA oil immersion and analyzed with Zeiss LSM software (Jena, Germany).
Generation of stably transfected U937 cell line expressing mRFP-
GFP-LC3B
ptfLC3 (mRFP-GFP-LC3) plasmid was a gift from Tamotsu Yoshimori
(Addgene plasmid # 21074, Cambridge, MA, USA). U937 cells (2 × 106) were
transfected with 10 μg of linearized and puriﬁed plasmid using the Neon
Transfection system as described above. Cells stably expressing mRFP-GFP-
LC3 were selected in medium supplemented with 400 μg/ml G418 during
2 weeks. After selection, cells were expanded and maintained in medium
containing 250 μg/ml G418.
For ﬂuorescence microscopy, cells were seeded on chambered cover-
slips (Nunc Lab-Tek II) with pharmacological agents of interest. Images
were acquired on a Leica TCS SP2 AOBS confocal microscope using a plan-
apochromat × 63 1.4 NA oil immersion with × 4 digital zoom and images
were analyzed with ImageJ software (Bethesda, MD, USA) and Adobe
Photoshop CS version 8.0 software.
Statistical analysis
Data are presented as mean± standard error of the mean (S.E.M.) from the
number of experiment indicated. Difference between two groups was
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determined by Student’s t-test and P-values o0.05 were considered
statistically signiﬁcant.
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